Skip to content
Bored Studies
RecruitingAccepts healthy volunteers

Intramyocellular Fatty Acid Trafficking in Insulin Resistance States - Effects of Intestinal Delivery of Lipids

Mayo Clinic · with National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · NCT03818178

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–55 · All sexes
Healthy volunteers
Accepted
Study type
Interventional · Not applicable
Target enrollment
60
US sites recruiting
1
Study start
December 1, 2018
Record last updated
January 12, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Muscle insulin resistance is a hallmark of upper body obesity (UBO) and Type 2 diabetes (T2DM). It is unknown whether muscle free fatty acid (FFA) availability or intramyocellular fatty acid trafficking is responsible for muscle insulin resistance, although it has been shown that raising FFA with Intralipid can cause muscle insulin resistance within 4 hours. The investigators do not understand to what extent the incorporation of FFA into ceramides or diacylglycerols (DG) affect insulin signaling and muscle glucose uptake. The investigators propose to alter the profile and concentrations of FFA of healthy, non-obese adults using an overnight, intra-duodenal palm oil infusion vs. an overnight intra-duodenal Intralipid infusion (both compared to saline control). The investigators will compare the muscle FFA storage into intramyocellular triglyceride, intramyocellular fatty acid trafficking, activation of the insulin signaling pathway and glucose disposal rates, providing the first measure of how different FFA profiles alter muscle FFA trafficking and insulin action at the whole body and cellular/molecular levels. By identifying which steps in the insulin signaling pathway are most affected, the investigators will determine the site-specific effect of ceramides and/or DG on different degrees of insulin resistance.

Hypothesis 1: Palm oil infusion will result in abnormal FFA trafficking into intra-myocellular ceramides and abnormal insulin signaling.

Hypothesis 2: Intralipid infusion will result in abnormal FFA trafficking into intra-myocellular saturated DG and abnormal insulin signaling.

Being studied: Intralipid; Palm Oil Emulsion; Saline

Conditions: Insulin Resistance

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Women and Men (Women premenopausal)
  • BMI 18-27
  • Weight stable
  • Not pregnant/nursing

Exclusion Criteria

  • Ischemic heart disease
  • Atherosclerotic valvular disease
  • Smokers (> 20 cigarettes per week)
  • Bilateral oophorectomy
  • Concomitant use of medications that can alter serum lipid profile (high dose fish oil, statins, niacin, fibrates, thiazolinediones, beta-blockers, atypical antipsychotics)
  • Lidocaine allergy

Recruiting US locations

  • Mayo Clinic

    Rochester, MN 55905

    Site contact: Pamela A Reich, SC · 507-255-6062 · reich.pamela@mayo.edu

Study contacts (from the official record)

  • Pamela Reich · 507-255-6062 · Reich.Pamela@mayo.edu
All diabetes studies in Minnesota →
Intramyocellular Fatty Acid Trafficking in Insulin Resistance… (NCT03818178) | Bored Studies